The stock of Radius Health, Inc. (NASDAQ:RDUS) is a huge mover today! The stock decreased 1.76% or $0.54 during the last trading session, reaching $30.21. About 411,624 shares traded. Radius Health, Inc. (NASDAQ:RDUS) has declined 19.42% since June 14, 2017 and is downtrending. It has underperformed by 31.99% the S&P500. Some Historical RDUS News: ; 14/05/2018 – Radius Health Presenting at Bank of America Conference Tomorrow; 22/03/2018 – Radius Health Provides Update on CHMP Opinion for Abaloparatide-SC; 10/05/2018 – Radius Health 1Q Loss/Shr $1.37; 11/04/2018 – Radius Health at Deutsche Bank Health Care Conference May 8; 20/04/2018 – Radius Health Presenting at Bank of America Conference May 15; 22/03/2018 – Radius Health: Intends to Appeal and Immediately Seek Re-Examination of CHMP Opinion; 21/04/2018 – DJ Radius Health Inc, Inst Holders, 1Q 2018 (RDUS); 07/05/2018 – Radius Health at Deutsche Bank Health Care Conference Tomorrow; 12/03/2018 – Radius Health Forms Golden Cross: Technicals; 08/03/2018 FBO:Veteran Aff: Veterans Affairs Contract Award – Q–Radius Health 02/15/2018 – 02/14/2023 – M5Q50A03R7The move comes after 5 months negative chart setup for the $1.37B company. It was reported on Jun, 14 by Barchart.com. We have $28.70 PT which if reached, will make NASDAQ:RDUS worth $68.65 million less.
Geo Group Inc (the) Reit (NYSE:GEO) had a decrease of 22.58% in short interest. GEO’s SI was 2.10M shares in June as released by FINRA. Its down 22.58% from 2.71 million shares previously. With 923,900 avg volume, 2 days are for Geo Group Inc (the) Reit (NYSE:GEO)’s short sellers to cover GEO’s short positions. The SI to Geo Group Inc (the) Reit’s float is 1.75%. The stock increased 0.97% or $0.24 during the last trading session, reaching $24.94. About 193,479 shares traded. The GEO Group, Inc. (NYSE:GEO) has declined 21.43% since June 14, 2017 and is downtrending. It has underperformed by 34.00% the S&P500. Some Historical GEO News: ; 19/04/2018 – DJ GEO Group Inc, Inst Holders, 1Q 2018 (GEO); 26/04/2018 – GEO Group Sees 2018 Adj EPS $1.30-Adj EPS $1.38; 26/04/2018 – GEO Group 1Q EPS 29c; 29/03/2018 – GEO GROUP INC – CONTRACT WILL HAVE A BASE TERM OF EIGHT YEARS EFFECTIVE JANUARY 26, 2019 WITH A RENEWAL OPTION PERIOD OF FOUR YEARS; 09/04/2018 – NJ WARN NOTICE FOR LOGAN HALL/GEO GROUP AFFECTS 54 IN NEWARK; 26/04/2018 – GEO GROUP INC GEO.N SEES FY 2018 ADJUSTED FFO SHR $2.45 TO $2.53; 26/04/2018 – GEO Group Sees 2018 EPS $1.27-EPS $1.35; 26/04/2018 – GEO Group 1Q Net $35M; 26/04/2018 – GEO GROUP INC QTRLY NORMALIZED FFO OF $0.43 PER DILUTED SHARE; 06/03/2018 Geo Group Conference Call Set By Stuart Frankel for Mar. 14
Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. The company has market cap of $1.37 billion. The Company’s product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. It currently has negative earnings. The firm is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer.
Since March 2, 2018, it had 6 buys, and 0 sales for $10.06 million activity. 40,000 shares valued at $1.16M were bought by BIOTECH GROWTH N V on Wednesday, May 23.
Analysts await Radius Health, Inc. (NASDAQ:RDUS) to report earnings on August, 2. They expect $-1.32 earnings per share, up 16.46% or $0.26 from last year’s $-1.58 per share. After $-1.37 actual earnings per share reported by Radius Health, Inc. for the previous quarter, Wall Street now forecasts -3.65% EPS growth.
More news for Radius Health, Inc. (NASDAQ:RDUS) were recently published by: Globenewswire.com, which released: “Radius to Host Investor Day on June 8, 2018” on June 05, 2018. Nasdaq.com‘s article titled: “Radius Health to Present at the Goldman Sachs 39th Annual Global Healthcare Conference” and published on June 07, 2018 is yet another important article.
Investors sentiment decreased to 0.79 in Q1 2018. Its down 0.57, from 1.36 in 2017Q4. It fall, as 19 investors sold Radius Health, Inc. shares while 43 reduced holdings. 19 funds opened positions while 30 raised stakes. 54.99 million shares or 2.61% more from 53.59 million shares in 2017Q4 were reported. Highland Capital Management Limited Partnership owns 35,000 shares or 0.06% of their US portfolio. Salzhauer Michael owns 7,500 shares for 0.1% of their portfolio. Blackrock reported 3.02M shares stake. Sei Investments Company holds 0.01% or 72,878 shares in its portfolio. Orbimed Advsrs Lc stated it has 0.34% in Radius Health, Inc. (NASDAQ:RDUS). Strs Ohio invested in 0% or 200 shares. Weiss Asset Mngmt Limited Partnership stated it has 13,046 shares or 0.04% of all its holdings. Legal General Public Ltd Llc accumulated 16,067 shares. 110,226 were reported by Jpmorgan Chase And. Cubist Systematic Strategies Ltd Llc reported 100 shares or 0% of all its holdings. Moreover, Lpl Fincl Ltd Liability Co has 0% invested in Radius Health, Inc. (NASDAQ:RDUS). Hudson Bay Cap Mngmt Limited Partnership invested in 0.12% or 160,000 shares. 3,266 are held by Ameritas Investment Prtn Inc. Bnp Paribas Arbitrage Sa owns 8,344 shares for 0% of their portfolio. Price T Rowe Assocs Md holds 0.03% in Radius Health, Inc. (NASDAQ:RDUS) or 5.09M shares.
Among 12 analysts covering Radius Health (NASDAQ:RDUS), 8 have Buy rating, 0 Sell and 4 Hold. Therefore 67% are positive. Radius Health had 34 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating by Cantor Fitzgerald given on Sunday, June 4. The firm has “Neutral” rating given on Wednesday, March 30 by Goldman Sachs. Jefferies maintained the stock with “Hold” rating in Monday, September 4 report. On Thursday, August 3 the stock rating was maintained by Jefferies with “Hold”. The stock of Radius Health, Inc. (NASDAQ:RDUS) earned “Buy” rating by H.C. Wainwright on Wednesday, September 21. The firm has “Buy” rating by Cantor Fitzgerald given on Sunday, July 23. The stock of Radius Health, Inc. (NASDAQ:RDUS) has “Buy” rating given on Monday, June 5 by Canaccord Genuity. The rating was maintained by Canaccord Genuity on Thursday, September 24 with “Buy”. The firm has “Hold” rating by Citigroup given on Wednesday, December 6. On Monday, May 23 the stock rating was initiated by H.C. Wainwright with “Buy”.
Among 5 analysts covering The GEO Group (NYSE:GEO), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. The GEO Group had 14 analyst reports since August 4, 2015 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Friday, November 11. The firm has “Buy” rating by Canaccord Genuity given on Thursday, August 10. The stock has “Buy” rating by Canaccord Genuity on Wednesday, August 24. The rating was maintained by Canaccord Genuity with “Buy” on Friday, February 24. As per Thursday, September 1, the company rating was maintained by Suntrust Robinson. The rating was maintained by Canaccord Genuity on Tuesday, April 11 with “Buy”. The stock has “Buy” rating by SunTrust on Wednesday, January 31. The stock of The GEO Group, Inc. (NYSE:GEO) earned “Buy” rating by J.P. Morgan on Friday, July 14. The stock of The GEO Group, Inc. (NYSE:GEO) has “Buy” rating given on Wednesday, October 18 by SunTrust. SunTrust maintained the shares of GEO in report on Thursday, September 1 with “Buy” rating.